MAPK8 and non-small cell lung carcinoma: Therefore,we found that JNK inhibition at low cisplatin concentrationsis highly effective at killing non-small-cell lung cancer A549 cells.Since both A549 and DLD-1 cell lines harbor activating KRAS mutations (Cellosaurus.org, 2023), we hypothesize that the differencein JNK functions at different concentrations of cisplatin may be dueto increased KRAS activity.